The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
27-Jul-21
Undisclosed
Target:
Pulsant Limited
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
27-May-21
$1.4 billion
Target:
Equiniti Group PLC
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
30-Sep-20
Undisclosed
Target:
WEX Inc. - Brazilian Operations/Subsidiary
Acquiror:
Vila Rica Capital
Advised WEX Inc., a leading fleet and B2B payments company, on the divestiture of its Brazilian subsidiary to Vila Rica Capital.
22-Sep-20
$NA
Target:
VX Fiber
Acquiror:
AMP Capital
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
29-Jul-20
$NA
Target:
Community Fibre Limited
Acquiror:
Warburg Pincus LLC, Deutsche Telekom Capital Partners
Advised Warburg Pincus LLC and Deutsche Telekom Capital Partners on the acquisition of a majority stake in CommunityFibre Limited, a leading full fibre network infrastructure platform in UK
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
02-Mar-20
$NA
Target:
Global rights (excluding North America) to ThermaCare (United Kingdom)
Acquiror:
Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
20-Feb-20
$NA
Target:
Asia and US rights to Physiogel
Acquiror:
LG Household & Health Care
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
28-Jun-19
$NA
Target:
Flormel
Acquiror:
Unbox Capital
Advised the shareholders of Flormel, a leader in healthy snacks and indulgences in Brazil, manufacturing snacks, snack bars, candies, chocolates, and other premium packaged food products, on the sale of a minority stake to Unbox Capital, the investment arm of the controlling shareholders of Magazine Luiza, one of the largest retailers in Brazil
17-Jun-19
$80 million
Target:
Renewi Canada
Acquiror:
Convent Capital
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
29-May-19
$NA
Target:
Pravaler
Acquiror:
Itaú Unibanco
Advising IFC and Principia Capital Partners on the sale of their stakes in Pravaler, Brazil’s leading provider of student loans for college students, to Itaú Unibanco, Brazil’s largest financial institution
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
22-Jul-18
$NA
Target:
Cura Imagem e Diagnóstico Ltda.
Acquiror:
Vinci Partners
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners